Literature DB >> 19085111

Method to screen substrates of apical sodium-dependent bile acid transporter.

Rana Rais1, Pablo M Gonzalez, Xiaowan Zheng, Stephen A Wring, James E Polli.   

Abstract

Human apical sodium-dependent bile acid transporter (hASBT) is a potential prodrug target under study. Development of prodrugs that target hASBT may yield compounds with low solubility and/or susceptibility to hydrolysis. A transport uptake method is needed that increases compound solubility and avoids NaOH for cell lysis during postexperimental cell sample preparation. The overall goal was to develop an assay method to screen for hASBT uptake of novel compounds. The first objective was to determine the maximum cosolvent concentrations that are compatible with an hASBT active transport assay. The second objective was to develop a NaOH-free cell lysis method to process cell samples from these uptake studies. The following cosolvents were studied: dimethylacetamide (DMAC), dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethanol, methanol, polyethylene glycol-400, propylene glycol, and dioxane. Initial studies included taurocholate flux studies across hASBT-Madin-Darby canine kidney monolayers using up to 10% cosolvent, as well as cytotoxicity studies. The effect of selected cosolvent concentrations on the hASBT Michaelis-Menten kinetic parameters was evaluated. Additionally, two acetonitrile-based cell lysis methods that do not use NaOH were evaluated in terms of percent sample recovery and hASBT kinetic parameters. Results showed that the maximum permissible cosolvent concentrations for hASBT uptake studies, without compromising assay results or causing cytotoxicity, are 1% DMAC, 1% DMF, 2.5% DMSO, 2.5% methanol, and 2.5% ethanol. Additionally, both NaOH-free, acetonitrile-based cell lysis methods provided similar recovery and hASBT results, compared to NaOH method. Hence, an assay method was developed to screen for active transport, allowing for cosolvents that can solubilize compounds and avoid NaOH sample treatment, which can otherwise degrade compound.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19085111      PMCID: PMC2628203          DOI: 10.1208/s12248-008-9069-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  20 in total

1.  Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures.

Authors:  Georges Da Violante; Naima Zerrouk; Isabelle Richard; Gérard Provot; Jean Claude Chaumeil; Philippe Arnaud
Journal:  Biol Pharm Bull       Date:  2002-12       Impact factor: 2.233

2.  Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells.

Authors:  M M Nerurkar; N F Ho; P S Burton; T J Vidmar; R T Borchardt
Journal:  J Pharm Sci       Date:  1997-07       Impact factor: 3.534

3.  Increased acyclovir oral bioavailability via a bile acid conjugate.

Authors:  Sanna Tolle-Sander; Kimberley A Lentz; Dean Y Maeda; Andrew Coop; James E Polli
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

4.  Modified acetonitrile protein-precipitation method of sample preparation for drug assay by liquid chromatography.

Authors:  J C Mathies; M A Austin
Journal:  Clin Chem       Date:  1980-11       Impact factor: 8.327

5.  The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.

Authors:  B J Aungst; N H Nguyen; J P Bulgarelli; K Oates-Lenz
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers.

Authors:  P Saha; J H Kou
Journal:  Eur J Pharm Biopharm       Date:  2000-11       Impact factor: 5.571

7.  Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT).

Authors:  Anand Balakrishnan; Daniel J Sussman; James E Polli
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 8.  The effects of drugs on membrane fluidity.

Authors:  D B Goldstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

9.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers.

Authors:  Bhagwant D Rege; Joseph P Y Kao; James E Polli
Journal:  Eur J Pharm Sci       Date:  2002-09       Impact factor: 4.384

10.  Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs.

Authors:  Yutaka Takahashi; Hiromu Kondo; Tatsuo Yasuda; Takashi Watanabe; Shin-Ichiro Kobayashi; Shigeharu Yokohama
Journal:  Int J Pharm       Date:  2002-10-10       Impact factor: 5.875

View more
  11 in total

1.  Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups.

Authors:  Vidula Kolhatkar; James E Polli
Journal:  Eur J Pharm Sci       Date:  2012-03-03       Impact factor: 4.384

2.  Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.

Authors:  Xiaowan Zheng; Lei Diao; Sean Ekins; James E Polli
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

3.  Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid.

Authors:  Xiaowan Zheng; Yongmei Pan; Chayan Acharya; Peter W Swaan; James E Polli
Journal:  Bioconjug Chem       Date:  2010-10-22       Impact factor: 4.774

4.  Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates.

Authors:  Rana Rais; Chayan Acharya; Alexander D Mackerell; James E Polli
Journal:  Mol Pharm       Date:  2010-11-01       Impact factor: 4.939

5.  Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters.

Authors:  Xiaowan Zheng; James Polli
Journal:  Eur J Pharm Sci       Date:  2010-05-27       Impact factor: 4.384

6.  Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT.

Authors:  Xiaowan Zheng; James E Polli
Journal:  Int J Pharm       Date:  2010-07-01       Impact factor: 5.875

7.  Reliability of inhibition models to correctly identify type of inhibition.

Authors:  Vidula Kolhatkar; James E Polli
Journal:  Pharm Res       Date:  2010-08-14       Impact factor: 4.200

8.  Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity.

Authors:  Diana Vivian; Kunrong Cheng; Sandeep Khurana; Su Xu; Valerie Whiterock; Drew Witter; Kimberley A Lentz; Kenneth S Santone; Jean-Pierre Raufman; James E Polli
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

9.  Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).

Authors:  Zhongqi Dong; Sean Ekins; James E Polli
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

10.  Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver.

Authors:  Diana Vivian; James E Polli
Journal:  Int J Pharm       Date:  2014-09-16       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.